Atara Biotherapeutics, Inc. announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel or Ebvallo)
South Korea�s Ministry of Food and Drug Safety (MFDS) has upheld its conditional approval of Olita Tab (olmutinib) (also known...
Atara Biotherapeutics announced that the Marketing Authorization Application (MAA) for tab-cel (tabelecleucel) has been fully validated by the European Medicines Agency (EMA).
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, announced the first patient has been dosed with imlifidase in the GOOD-IDES-02 trial, a global pivotal phase III trial in anti-glomerular basement membrane (anti-GBM) disease
Hansa Biopharma AB, the pioneer in immunomodulatory enzyme technology for rare IgG-mediated diseases, announces the publication of important data from an investigator-initiated study in anti-GBM in leading nephrology journal Journal of the American Society of Nephrology (JASN).
Kissei Pharmaceutical Co., Ltd. announced that the Ministry of Health, Labour and Welfare (MHLW) has granted manufacturing and marketing approval to Kissei for the oral spleen tyrosine kinase (SYK) inhibitor, Tavalisse Tab. 100mg and 150mg (generic name: fostamatinib disodium hexahydrate, development code: R788), for chronic idiopathic thrombocytopenic purpura (chronic ITP).